Plus Therapeutics (NASDAQ:PSTV) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a report issued on Friday,Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright also issued estimates for Plus Therapeutics’ FY2028 earnings at $0.28 EPS.

Separately, Ascendiant Capital Markets cut their target price on Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd.

Plus Therapeutics Stock Up 1.7 %

NASDAQ PSTV opened at $1.19 on Friday. The firm has a market cap of $7.02 million, a P/E ratio of -0.47 and a beta of 0.69. The business’s 50-day moving average price is $1.40 and its 200 day moving average price is $1.66. Plus Therapeutics has a 52-week low of $1.15 and a 52-week high of $2.67.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics as of its most recent SEC filing. Institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.